A randomized phase 3 clinical trial compared the effectiveness of nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first-line chemotherapy for patients with recurrent or metastatic nasopharyngeal carcinoma. The results were published in BMJ 2024, with the study showing promising outcomes for the nab-paclitaxel combination in improving survival rates and reducing tumor progression. This suggests that nab-paclitaxel, cisplatin, and capecitabine may be a more effective treatment option for patients with advanced nasopharyngeal carcinoma compared to the standard cisplatin and gemcitabine regimen.
Source link
Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial
